No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
GANX241220C4000
- 0.10
- 0.000.00%
15min DelayClose Dec 20 16:00 ET
0.00High0.00Low
0.10Open0.10Pre Close0 Volume100 Open Interest4.00Strike Price0.00Turnover0.00%IV162.82%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma15.60Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Gain Therapeutics To Present At Biotech Showcase 2025
H.C. Wainwright Maintains Gain Therapeutics(GANX.US) With Buy Rating, Cuts Target Price to $7
Gain Therapeutics Price Target Announced at $7.00/Share by Roth MKM
Gain Therapeutics Initiated at Buy by Roth MKM
Promising Preclinical Data and Financial Position Support Buy Rating for Gain Therapeutics
Chardan Capital Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $6